Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Immune Response in Peripheral Blood of Patients With Colon Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Arizona
ClinicalTrials.gov Identifier:
NCT00900432
First received: May 9, 2009
Last updated: August 13, 2012
Last verified: August 2012

May 9, 2009
August 13, 2012
July 2004
December 2008   (final data collection date for primary outcome measure)
Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00900432 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Immune Response in Peripheral Blood of Patients With Colon Cancer
Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells.

PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer.

OBJECTIVES:

  • Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from the peripheral blood of patients with colon cancer.

OUTLINE: This is an open-label study.

Patients undergo blood collection at time of follow-up, surgery, thoracentesis, paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides (carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by ELISA, ELISPOT, or intracellular flow.

PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

colon cancer

Colorectal Cancer
  • Other: immunoenzyme technique
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
67
December 2008
December 2008   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of colon cancer

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00900432
04-0331-01, P50CA095060, P30CA023074, UARIZ-04-81
Not Provided
University of Arizona
University of Arizona
National Cancer Institute (NCI)
Study Chair: Michael Demeure, MD University of Arizona
University of Arizona
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP